Results 201 to 210 of about 49,612 (306)

Contrast‐enhanced ultrasonography vs MRI for indeterminate testicular lesions: a systematic review and meta‐analysis

open access: yesBJU International, Volume 138, Issue 1, Page 57-67, July 2026.
Objective To conduct a systematic review and meta‐analysis to indirectly compare the diagnostic performance of contrast‐enhanced ultrasonography (CEUS) and magnetic resonance imaging (MRI) in the evaluation of indeterminate testicular lesions and to explore their potential roles in guiding clinical decision‐making.
Muhammed Arif Ibis   +14 more
wiley   +1 more source

High Prevalence of Metabolic Dysfunction–Associated Steatohepatitis With Significant Fibrosis in Primary Care and Endocrinology Clinics

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 6184-6193, July 2026.
ABSTRACT Aims Metabolic dysfunction‐associated steatohepatitis (MASH) is a leading cause of cirrhosis. NIS2+ is a recently approved serum‐based test combining two biomarkers (miR‐34a‐5p and YKL‐40) to identify at‐risk MASH (i.e., MASH and significant fibrosis). Objective To assess the prevalence of at‐risk MASH by NIS2+ in individuals from primary care
Srilaxmi Kalavalapalli   +12 more
wiley   +1 more source

Non-invasive ultrasound assessment of chronic liver disease: current position and future directions for a "one-stop" liver ultrasound approach. [PDF]

open access: yesInsights Imaging
Sidhu PS   +10 more
europepmc   +1 more source

Steatotic Liver Disease at Primary Biliary Cholangitis Diagnosis: Association With Ursodeoxycholic Acid Response and Outcomes

open access: yesLiver International, Volume 46, Issue 7, July 2026.
ABSTRACT Background and Aim Steatotic liver disease (SLD) is becoming increasingly prevalent, leading to a higher frequency of primary biliary cholangitis (PBC) cases coexisting with SLD. However, data on its impact in patients with PBC remain scarce.
María Del Barrio   +38 more
wiley   +1 more source

Summative Comorbidities Are Independently Associated With Mortality in Patients With Hepatocellular Carcinoma

open access: yesLiver International, Volume 46, Issue 7, July 2026.
ABSTRACT Background Comorbidities might limit therapeutic options and negatively impact survival in patients with hepatocellular carcinoma (HCC). The Charlson Comorbidity Index (CCI) is widely used to summarize and quantify comorbidities. Methods HCC patients diagnosed between 1992 and 2018 at the Medical University of Vienna were retrospectively ...
Tobias Meischl   +12 more
wiley   +1 more source

Socioeconomic Factors and Their Role in Metabolic Dysfunction‐Associated Steatotic Liver Disease: A Comprehensive Review

open access: yesLiver International, Volume 46, Issue 7, July 2026.
ABSTRACT Metabolic dysfunction‐associated steatotic liver disease (MASLD), a major public health concern, is influenced by an interplay of genetic, environmental, and lifestyle factors, with socioeconomic factors functioning as important upstream determinants whose roles remain not yet fully understood.
Leke Wiering, Münevver Demir
wiley   +1 more source

Validation of Risk Models for Predicting Post‐SVR HCC in Real‐World Surveillance Across Global Geographic Regions

open access: yesLiver International, Volume 46, Issue 7, July 2026.
ABSTRACT Background & Aims Several clinical risk models have been proposed to stratify hepatocellular carcinoma (HCC) risk in patients with chronic hepatitis C virus (HCV) after sustained virologic response (SVR). However, validation efforts have focused on monocentric or country‐specific cohorts, and it is unclear if clinical risk models can be ...
Hidenori Toyoda   +36 more
wiley   +1 more source

Home - About - Disclaimer - Privacy